Long-term therapy with bevacizumab in a young patient affected by NF-2

Nigro, Olga; Tartaro, Tiziana; Tuzi, Alessandro; Giaquinto, Alice; Suter, Matteo B.; Pinotti, Graziella

doi:10.1097/cad.0000000000000732

Cited by 2 publications

(2 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VS tumours express vasculo-endothelial growth factor (VEGF) on immunohistochemical profiling (Li et al, 2016;Mautner et al, 2010;Plotkin, Stemmer-Rachamimov, et al, 2009). Several studies have investigated the effect bevacizumab, an antiangiogenic agent specifically targeting VEGF, to reduce the volume and associated hearing impairment related to VS tumours (Alanin et al, 2015;Hochart et al, 2015;Huang et al, 2018;Mautner et al, 2010;Morris et al, 2016;Nigro et al, 2019;Plotkin, Stemmer-Rachamimov, et al, 2009). In a cohort of ten patients with ten index tumours, nine tumours showed treatment effect, and four patients maintained response during 11-16 month follow up (Plotkin, Stemmer-Rachamimov, et al, 2009).…”

Section: Bevacizumab In Neurofibromatosis Typementioning

confidence: 99%

“…There have been multiple studies investigating systemic options for NF2 related VS. Systemic treatment is complicated by the elusiveness of the blood-brain barrier, and multiple monoclonal antibody and small molecule inhibitor agents have been proposed (Evans et al, 2009;Goutagny & Kalamarides, 2018;Karajannis et al, 2012;Nigro et al, 2019).…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2

Ardern‐Holmes

White

Bahure

et al. 2021

Australasian Journal of Neuroscience

View full text Add to dashboard Cite

Introduction:We describe an Australian experience of infusional bevacizumab for vestibular schwannoma (VS) in neurofibromatosis type 2 patients, with specific focus on 3-dimensional tumour volume and audiometry.Method: Data was pooled from patients with symptomatic or progressive VS from 2009 to April 2018. Tumours were assessed as total volume per patient. Bevacizumab infusions were administered every 2-4 weeks. 3-D volumetric response (cm 3 ) was determined through serial magnetic resonance imaging, at baseline and at 3-6-month intervals, until cessation of infusions following progression or prior to surgery. Volumetric response was defined as a reduction of volume ³ 20%, from baseline. Patients underwent interval pure tone audiometry. A decrease in the average pure tone analyses by 10dB indicated response.Results: Twenty-one VS tumours were identified in eleven patients. Median age was 26 (range 13 -67yr). Average baseline tumour volume was 14.17cm 3 (range 1.45cm 3 -38.51cm 3 ). Tumour volume reduction >20% was shown in 7/11 patients (64%), indicating partial response, 2/11 (18%) patients showed stable disease, and 2/11 (18%) progressed. Average percentage tumour volume change was +4.45% from baseline (range -57% to 241%). 16 individual ears were tested, 3/16 (19%) of ears showed an average decibel reduction of 10dB or more, indicating response (average change 2.5dB, range -36dB to 81dB). 10/16 (63%) showed stable hearing, and 3/16 (19%) showed hearing deterioration. Conclusion:Bevacizumab is a useful agent for reducing tumour volume and improving hearing losses due to vestibular schwannoma in neurofibromatosis type 2 patients. These results reflect results described from the United Kingdom and United States.

show abstract

Section: Bevacizumab In Neurofibromatosis Typementioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2

Ardern‐Holmes

White

Bahure

et al. 2021

Australasian Journal of Neuroscience

View full text Add to dashboard Cite

show abstract

Long-term therapy with Bevacizumab in a young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature

et al. 2020

View full text Add to dashboard Cite

Neurofibromatosis type 2 (NF2) is an autosomal dominant condition caused by pathogenic variants in the NF2 gene. To date, cytotoxic chemotherapy has no established role in the treatment of NF-2. Historical case reports of malignant schwannomas have documented responses to chemotherapies with cyclophosphamide, vincristine and doxorubicin, in patients who develop pulmonary metastases. Recently, several studies proposed the use of anti-HER2, anti-EGFR, anti-platelet-derived growth factor receptors. As reported in our previous review of the literature, vascular endothelial growth factor (VEGF) and its receptor VEGFR-1 have been detected in schwannomas with the best results. We described the case of a young patient with NF2 treated for long time with Bevacizumab. Here, we report the update of the previous case report.

show abstract

Long-term therapy with bevacizumab in a young patient affected by NF-2

Cited by 2 publications

References 33 publications

The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2

The Effect of Bevacizumab on Vestibular Schwannoma Related to Neurofibromatosis Type 2

Long-term therapy with Bevacizumab in a young patient affected by NF2. Stop or continue treatment? An update of a case report and review of the literature

Contact Info

Product

Resources

About